Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677105 | 0.92 | GRM5 (0.61) | GRM5THRBHTR1AHTR2AHTR7 | |
| SCHEMBL4711789 | 0.91 | GRM5 (0.71) | GRM5THRBHTR1AHTR2AHTR7 | |
| SCHEMBL13677078 | 0.91 | GRM5 (0.62) | GRM5THRBHTR1AHTR2AHTR7 | |
| SCHEMBL13677110 | 0.90 | GRM5 (0.61) | GRM5THRBHTR1AHTR2AHTR7 | |
| SCHEMBL13677100 | 0.90 | GRM5 (0.75) | GRM5THRBHTR1AHTR2AHTR7 | |
| SCHEMBL13677092 | 0.90 | GRM5 (0.60) | GRM5 | |
| SCHEMBL13677104 | 0.90 | THRB (0.61) | GRM5THRBHTR1AHTR2AHTR7 | |
| SCHEMBL4710251 | 0.88 | GRM5 (0.63) | GRM5THRBHTR1AHTR2AHTR7 | |
| SCHEMBL13677102 | 0.88 | GRM5 (0.63) | GRM5THRBHTR1AHTR2AHTR7 | |
| SCHEMBL13677109 | 0.87 | GRM5 (0.60) | GRM5THRBHTR1AHTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2009-10-29 | — | — | US | disclosed |
| EP-1962849-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | Richter Gedeon NYRT (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072093-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270371-A1 | QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS | GRM5, GRIK5, GRM1 | GRM5 1/4885THRB 670/4885HTR1A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.